HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immune gene polymorphisms associated with poor response to platelet transfusion and recombinant factor VII administration in Glanzmann thrombasthenia.

AbstractINTRODUCTION:
Poor response to platelet and recombinant factor VII administration is a major problem in patients with Glanzmann Thrombasthenia (GT). The risk factors associated with poor response to treatment in these patients are unknown. Some genetic variations of cytokines may contribute to therapy resistance.
AIMS:
We evaluated, for the first time, whether genetic polymorphisms on cytokine genes are related to poor treatment response in GT patients.
METHODS:
We enrolled 30 patients with GT (15 resistant and 15 non-resistant) and 100 healthy controls. Gene polymorphisms of IL-10 and TNF-α were analysed using TaqMan Realtime PCR, and IL-1, IL-1R1 and IL-1RN were investigated with the RFLP method. In-silico analyses were performed to predict the potential impact of these polymorphisms.
RESULTS:
In the resistant group, all patients had a variant of the IL-10 gene at the -1082 position (rs1800896), with a GG genotype that was significantly more frequent than the non-resistant group. Analysis between healthy controls and GT patients revealed a probable correlation between rs3783550, rs3783553, rs3917356 and rs2234463 and GT. The In-silico study indicated that TNF-α rs1800629 and IL-10 rs1800896 polymorphisms result in different allelic expressions which may contribute to poor response to therapy.
CONCLUSIONS:
These findings suggest that polymorphisms in the IL-10 and IL-1 receptor antagonist genes may play a role in poor therapy response in GT patients. In addition, some polymorphisms in IL-1α, IL1-β, IL-1R1 and IL-R antagonists might be involved in the GT progression.
AuthorsMajid Naderi, Ilia Mirzaei, Omid Seidizadeh, Abolfazl Parsi Moud, Hosna Sarani, Amir Avan, Mohsen Taheri, Danial Jahantigh, Mohammad Reza Keramati, Tayebeh Sohrabi
JournalHaemophilia : the official journal of the World Federation of Hemophilia (Haemophilia) Vol. 30 Issue 3 Pg. 752-764 (May 2024) ISSN: 1365-2516 [Electronic] England
PMID38439143 (Publication Type: Journal Article)
Copyright© 2024 John Wiley & Sons Ltd.
Chemical References
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-10
  • IL1RN protein, human
  • Recombinant Proteins
  • Tumor Necrosis Factor-alpha
  • Receptors, Interleukin-1 Type I
Topics
  • Humans
  • Male
  • Female
  • Thrombasthenia (genetics, drug therapy)
  • Interleukin 1 Receptor Antagonist Protein (genetics, therapeutic use)
  • Interleukin-10 (genetics)
  • Child
  • Polymorphism, Single Nucleotide
  • Recombinant Proteins (therapeutic use)
  • Adolescent
  • Genotype
  • Tumor Necrosis Factor-alpha (genetics, antagonists & inhibitors)
  • Child, Preschool
  • Receptors, Interleukin-1 Type I (genetics)
  • Adult
  • Case-Control Studies
  • Polymorphism, Genetic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: